Summary

The global endometriosis market was valued at USD 3,030.79 million in 2025 and is projected to reach USD 9,786.23 million by 2035. The market is expected to expand at a CAGR of 12.5% during the forecast period from 2026 to 2035, driven by rising awareness, improved diagnostic technologies, and increasing treatment adoption.

Rising Adoption of Hormonal Therapies Driving Market Growth
The use of hormonal therapies is rapidly increasing, which is the main factor enhancing the global endometriosis market. Besides offering pain relief, these medications can also inhibit oestrogen production and limit disease advancement, often eliminating the need for surgical procedures. The launch of more effective drugs, exemplified by AbbVie's Orilissa and Bayer's Visanne, is one of the reasons why patients from different parts of the world are more inclined to the notion of long-term treatment.

Segment-wise Market Overview
- NSAIDs - Widely used for temporary pelvic pain relief.
- Oral Contraceptives - Commonly prescribed for hormonal symptom management.
- Gonadotropin Releasing Hormone Agonists Antagonists - Effective in reducing oestrogen-driven tissue growth.
- Others - Includes emerging therapies and supportive medications.
- Acupuncture Therapy - Gaining attention for natural pain management.
- Surgery - Preferred for severe and advanced endometriosis cases.
- Hospitals & Clinics - Major centres for diagnosis and treatment.
- Homecare Settings - Increasing adoption of self-managed treatment approaches.
- Others - Includes specialty centres and ambulatory care facilities.

Due to the presence of sophisticated healthcare infrastructure, the availability of effective reimbursement systems, and the early adoption of innovative therapies, North America accounts for the largest share of the global endometriosis treatment market, while Europe continues to grow with the help of standardized care and widespread treatment access. Similarly, healthcare investment and awareness make Asia Pacific the fastest-growing market, whereas South America and the Middle East and Africa are witnessing gradual market expansion due to improving diagnosis and increasing treatment accessibility.

FDA Approval Strengthens Pfizer’s Women’s Health Portfolio
In August last year, Pfizer Inc. got the nod from the US FDA for MYFEMBREE. This will be the first once-daily oral medication for moderate to severe endometriosis pain in premenopausal women. Besides this, the clinical trials Phase 3 SPIRIT involving more than 1, 200 patients saw the medication marketing pharma companies to strengthen their position in women's healthcare therapeutics with a drug that not only reduces pain significantly but also has minimal impact on bone mineral density.

Rising Global Focus on Women’s Healthcare
Among other things, mounting worldwide investment in women's health is a major factor helping create strong growth opportunities for the endometriosis market. Governments and healthcare organizations prioritizing reproductive health awareness, diagnosis, and treatment accessibility are coming forward to open up the market further. Greater public understanding of the disease and its long-term effects on individuals' quality of life and productivity leads to accelerated research and healthcare funding.

Key Report Attributes
- Market Size 2025: USD 3,030.79 Million
- Market Size 2035: USD 9,786.23 Million
- CAGR (2026-2035): 12.5%
- Base Year: 2024
- Market Forecast Period: 2025-2035

Industry Segmentations Growth
- By Treatment Type: Medication - 13.5%, Acupuncture Therapy - 5.0%.
- By End User: Hospitals & Clinics - 12.0%, Homecare Settings - 14.2%.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY ....................... 17
1.1 MARKET ATTRACTIVENESS ANALYSIS ................... 18
1.2 GLOBAL ENDOMETRIOSIS TREATMENTMARKET, BY TREATMENT TYPE ................... 19
1.3 GLOBAL ENDOMETRIOSIS TREATMENTMARKET, BY END USE .................. 20
2 MARKET INTRODUCTION .................... 22
2.1 DEFINITION ........ 22
2.2 SCOPE OF THE STUDY .......... 22
2.3 RESEARCH OBJECTIVE ........ 22
2.4 MARKET STRUCTURE .......... 23
3 RESEARCH METHODOLOGY .............. 24
3.1 OVERVIEW .......... 24
3.2 DATA FLOW ........ 26
3.2.1 DATA MINING PROCESS ......................... 26
3.3 PURCHASED DATABASE: ........................... 27
3.4 SECONDARY SOURCES: ........ 28
3.4.1 SECONDARY RESEARCH DATA FLOW: .......... 29
3.5 PRIMARY RESEARCH: ........... 30
3.5.1 PRIMARY RESEARCH DATA FLOW: ............ 31
3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED ...................... 32
3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE ..................... 32
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: ......................... 33
3.6.1 REVENUE ANALYSIS APPROACH .............. 33
3.7 DATA FORECASTING............. 34
3.7.1 DATA FORECASTING TYPE ....................... 34
3.8 DATA MODELING .................... 35
3.8.1 MICROECONOMIC FACTOR ANALYSIS: ......... 35
3.8.2 DATA MODELING: ........... 36
3.9 TEAMS AND ANALYST CONTRIBUTION ................... 38
4 MARKET DYNAMICS ...... 40
4.1 INTRODUCTION ....................... 40
4.2 DRIVERS ............... 41
4.2.1 INCREASING ADOPTION OF HORMONAL THERAPIES FOR SYMPTOM MANAGEMENT ................ 41
4.2.2 INCREASING PREVALENCE OF ENDOMETRIOSIS ...... 41
4.2.3 GROWING USE OF COMBINATION AND LONG-TERM DRUG THERAPIES .......... 42
4.2.4 INCREASING TREATMENT UPTAKE FOR ENDOMETRIOSIS-ASSOCIATED PAIN AND INFERTILITY ........................... 43
4.3 RESTRAINTS ...... 44
4.3.1 HIGH TREATMENT COSTS AND LIMITED REIMBURSEMENT IN SOME REGIONS .................... 44
4.3.2 SIDE EFFECTS ASSOCIATED WITH HORMONAL THERAPIES ............ 44
4.3.3 LACK OF CURATIVE TREATMENTS AND HIGH DISEASE RECURRENCE ............. 45
4.4 OPPORTUNITIES ..................... 46
4.4.1 INCREASING INVESTMENT IN WOMEN’S HEALTH .......................... 46
4.4.2 EXPANSION OF PIPELINE DRUGS AND CLINICAL RESEARCH ......................... 47
5 MARKET FACTOR ANALYSIS .............. 48
5.1 REGULATORY ENVIRONMENT & COMPLIANCE ........................... 48
5.2 TECHNOLOGICAL TRENDS & INNOVATION .............. 50
5.3 PATIENT DEMOGRAPHICS & DISEASE BURDENS ......................... 50
5.4 PRICING ANALYSIS & REIMBURSEMENT DYNAMICS ................ 51
5.4.1 NORTH AMERICA ............ 51
5.4.2 EUROPE ....................... 51
5.4.3 ASIA PACIFIC ................ 51
5.4.4 REST OF THE WORLD ......... 52
5.4.5 REIMBURSEMENT DYNAMICS .................. 52
5.5 MARKET ENTRY & EXIT BARRIERS ...... 52
5.5.1 BARRIERS TO ENTRY .......... 52
5.5.2 BARRIERS TO EXIT ............ 53
5.6 PARTNERSHIPS & COLLABORATIONS ........................ 53
5.7 CONSUMER & HEALTHCARE PROVIDER PREFERENCES ........... 54
5.7.1 CONSUMER PREFERENCES ..................... 54
5.7.2 HEALTHCARE PROVIDER PREFERENCES ...................... 54
5.8 PESTLE ANALYSIS ................. 55
5.8.1 POLITICAL FACTORS ........................ 55
5.8.2 ECONOMIC FACTORS .......................... 55
5.8.3 SOCIAL FACTORS ....... 55
5.8.4 TECHNOLOGICAL FACTORS .............. 56
5.8.5 LEGAL FACTORS ........ 56
5.8.6 ENVIRONMENTAL FACTORS ............. 56
5.9 PORTER'S FIVE FORCES MODEL ............. 57
5.9.1 THREAT OF NEW ENTRANTS ..................... 57
5.9.2 BARGAINING POWER OF SUPPLIERS ....................... 58
5.9.3 THREAT OF SUBSTITUTES ........................ 58
5.9.4 BARGAINING POWER OF BUYERS .............. 58
5.9.5 INTENSITY OF RIVALRY ...... 58
5.10 PRODUCT PIPELINE ANALYSIS ............... 59
5.11 CASE STUDY ANALYSIS ...... 59
5.12 INVESTMENT & FUNDING SCENARIOS ...................... 60
5.13 POST-MARKET SURVEILLANCE & SAFETY DATA ...................... 61
5.14 DISEASE OVERVIEW ............. 62
5.15 DIAGNOSIS .......... 62
5.16 CURRENT TREATMENT ...... 63
6 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE ...... 66
6.1 OVERVIEW .......... 66
7 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY END USER .................... 69
7.1 OVERVIEW .......... 69
8 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY REGION ........................ 71
8.1 OVERVIEW .......... 71
8.2 NORTH AMERICA ................... 73
8.2.1 US ........ 76
8.2.2 CANADA ....................... 77
8.3 EUROPE ................ 78
8.3.1 GERMANY ..................... 81
8.3.2 UK ....... 82
8.3.3 FRANCE ........................ 83
8.3.4 NETHERLANDS ................ 84
8.3.5 ITALY ........................... 85
8.3.6 SPAIN ......................... 86
8.3.7 REST OF EUROPE ............ 87
8.4 ASIA PACIFIC ........................... 88
8.4.1 CHINA ......................... 91
8.4.2 INDIA .......................... 92
8.4.3 JAPAN ......................... 93
8.4.4 SOUTH KOREA ................ 94
8.4.5 MALAYSIA .................... 95
8.4.6 THAILAND ...................... 96
8.4.7 INDONESIA ................... 97
8.4.8 REST OF ASIA PACIFIC ...... 98
8.5 LATAM ................. 100
8.5.1 BRAZIL ......................... 103
8.5.2 MEXICO ....................... 104
8.5.3 ARGENTINA.................... 105
8.5.4 REST OF LATIN AMERICA ........................ 106
8.6 MIDDLE EAST AND AFRICA ...................... 107
8.6.1 GCC COUNTRIES......... 109
8.6.2 SOUTH AFRICA ........... 111
8.6.3 REST OF MIDDLE EAST AND AFRICA .......... 112
9 COMPETITIVE LANDSCAPE ................ 115
9.1 INTRODUCTION ....................... 115
9.2 MARKET SHARE ANALYSIS, 2025 ......... 115
9.3 COMPETITOR DASHBOARD....................... 116
9.4 PUBLIC PLAYERS STOCK SUMMARY ......................... 117
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL ............ 117
9.1 KEY DEVELOPMENTS & GROWTH STRATEGIES .......................... 118
9.1.1 PRODUCT APPROVAL ........ 118
10 COMPANY PROFILES .......................... 119
10.1 PFIZER INC. ......... 119
10.1.1 COMPANY OVERVIEW ....................... 119
10.1.2 FINANCIAL OVERVIEW ...................... 120
10.1.3 PRODUCTS OFFERED ........................ 121
10.1.4 KEY DEVELOPMENTS ........................ 121
10.1.5 SWOT ANALYSIS ........ 121
10.1.6 KEY STRATEGIES ........ 122
10.2 MEDTRONIC ....... 123
10.2.1 COMPANY OVERVIEW ....................... 123
10.2.2 FINANCIAL OVERVIEW ...................... 124
10.2.3 PRODUCTS OFFERED ........................... 125
10.2.4 KEY DEVELOPMENTS ........................ 125
10.2.5 SWOT ANALYSIS ........ 125
10.2.6 KEY STRATEGIES ........ 126
10.3 ASTRAZENECA........................ 127
10.3.1 COMPANY OVERVIEW ....................... 127
10.3.2 FINANCIAL OVERVIEW ...................... 128
10.3.4 KEY DEVELOPMENTS ........................ 128
10.3.5 KEY STRATEGIES ........ 129
10.4 F. HOFFMANN-LA ROCHE LTD. ............... 130
10.4.1 COMPANY OVERVIEW ...................... 130
10.4.2 FINANCIAL OVERVIEW ...................... 131
10.4.4 KEY DEVELOPMENTS ........................ 132
10.4.5 KEY STRATEGIES ........ 132
10.5 HALEON PLC ...... 133
10.5.1 COMPANY OVERVIEW ....................... 133
10.5.2 FINANCIAL OVERVIEW ...................... 134
10.5.4 KEY DEVELOPMENTS ........................ 135
10.5.5 KEY STRATEGIES ........ 135
10.6 ABBVIE INC. ........ 136
10.6.1 COMPANY OVERVIEW ....................... 136
10.6.2 FINANCIAL OVERVIEW ...................... 137
10.6.3 PRODUCTS OFFERED ...... 137
10.6.4 KEY DEVELOPMENTS ........................ 137
10.6.5 SWOT ANALYSIS ........ 138
10.6.6 KEY STRATEGIES ........ 139
10.7 BAYER AG ........... 140
10.7.1 COMPANY OVERVIEW ....................... 140
10.7.2 FINANCIAL OVERVIEW ...................... 142
10.7.3 PRODUCTS OFFERED ........................... 143
10.7.4 KEY DEVELOPMENTS ........................ 143
10.7.5 SWOT ANALYSIS ........ 144
10.7.6 KEY STRATEGIES ........ 145
10.8 SANOFI ................. 146
10.8.1 COMPANY OVERVIEW ....................... 146
10.8.2 FINANCIAL OVERVIEW ...................... 147
10.8.3 PRODUCTS OFFERED ...... 148
10.8.4 KEY DEVELOPMENTS ........................ 148
10.8.5 SWOT ANALYSIS ........ 148
10.8.6 KEY STRATEGY ............... 149
10.9 TEVA PHARMACEUTICAL INDUSTRIES LTD. .......... 150
10.9.1 COMPANY OVERVIEW ....................... 150
10.9.2 FINANCIAL OVERVIEW ...................... 151
10.9.3 PRODUCTS OFFERED ...... 152
10.9.4 KEY DEVELOPMENTS ........................ 152
10.9.5 KEY STRATEGIES ........ 153
10.10 SUN PHARMACEUTICAL INDUSTRIES LTD. ............. 154
10.10.1 COMPANY OVERVIEW ....................... 154
10.10.2 FINANCIAL OVERVIEW ...................... 155
10.10.3 PRODUCTS OFFERED ........................... 156
10.10.4 KEY DEVELOPMENTS ........................ 156
10.10.5 KEY STRATEGIES ........ 156
10.11 DATA CITATIONS ................... 157

ページTOPに戻る

List of Tables/Graphs

LIST OF TABLES
TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 37
TABLE 2 NORTH AMERICA PRICING ANALYSIS, BY PRODUCT 51
TABLE 3 EUROPE PRICING ANALYSIS, BY PRODUCT 51
TABLE 4 ASIA PACIFIC PRICING ANALYSIS, BY PRODUCT 51
TABLE 5 REST OF THE WORLD PRICING ANALYSIS, BY PRODUCT 52
TABLE 6 PRODUCT PIPELINE 59
TABLE 7 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 67
TABLE 8 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2035 (USD MILLION) 68
TABLE 9 GLOBAL ENDOMETRIOSIS TREATMENT MARKET, END USER, 2019-2035 (USD MILLION) 70
TABLE 10 GLOBAL ENDOMETRIOSIS MARKET, BY REGION, 2019-2035 (USD MILLION) 72
TABLE 11 NORTH AMERICA ENDOMETRIOSIS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 74
TABLE 12 NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 75
TABLE 13 NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2035 (USD MILLION) 75
TABLE 14 NORTH AMERICA ENDOMETRIOSIS TREATMENT MARKET, END USER, 2019-2035 (USD MILLION) 75
TABLE 15 US ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 76
TABLE 16 US ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2035 (USD MILLION) 76
TABLE 17 US ENDOMETRIOSIS TREATMENT MARKET, END USER, 2019-2035 (USD MILLION) 76
TABLE 18 CANADA ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 77
TABLE 19 CANADA ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2035 (USD MILLION) 77
TABLE 20 CANADA ENDOMETRIOSIS TREATMENT MARKET, END USER, 2019-2035 (USD MILLION) 77
TABLE 21 EUROPE ENDOMETRIOSIS TREATMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 79
TABLE 22 EUROPE ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 80
TABLE 23 EUROPE ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 80
TABLE 24 EUROPE ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 80
TABLE 25 GERMANY ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 81
TABLE 26 GERMANY ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 81
TABLE 27 GERMANY ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 81
TABLE 28 UK ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 82
TABLE 29 UK ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 82
TABLE 30 UK ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 82
TABLE 31 FRANCE ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 83
TABLE 32 FRANCE ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 83
TABLE 33 FRANCE ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 83
TABLE 34 NETHERLANDS ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 84
TABLE 35 NETHERLANDS ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 84
TABLE 36 NETHERLANDS ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 84
TABLE 37 ITALY ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 85
TABLE 38 ITALY ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 85
TABLE 39 ITALY ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 85
TABLE 40 SPAIN ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 86
TABLE 41 SPAIN ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 86
TABLE 42 SPAIN ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 86
TABLE 43 REST OF EUROPE ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 87
TABLE 44 REST OF EUROPE ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 87
TABLE 45 REST OF EUROPE ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 87
TABLE 46 ASIA PACIFIC ENDOMETRIOSIS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 89
TABLE 47 ASIA PACIFIC ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 90
TABLE 48 ASIA PACIFIC ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 90
TABLE 49 ASIA PACIFIC ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 91
TABLE 50 CHINA ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 91
TABLE 51 CHINA ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 91
TABLE 52 CHINA ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 92
TABLE 53 INDIA ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 92
TABLE 54 INDIA ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 92
TABLE 55 INDIA ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 93
TABLE 56 JAPAN ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 93
TABLE 57 JAPAN ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 93
TABLE 58 JAPAN ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 94
TABLE 59 SOUTH KOREA ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 94
TABLE 60 SOUTH KOREA ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 94
TABLE 61 SOUTH KOREA ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 95
TABLE 62 MALAYSIA ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 95
TABLE 63 MALAYSIA ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 95
TABLE 64 MALAYSIA ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 96
TABLE 65 THAILAND ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 96
TABLE 66 THAILAND ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 96
TABLE 67 THAILAND ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 97
TABLE 68 INDONESIA ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 97
TABLE 69 INDONESIA ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 97
TABLE 70 INDONESIA ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 98
TABLE 71 REST OF ASIA PACIFIC ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 98
TABLE 72 REST OF ASIA PACIFIC ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 99
TABLE 73 REST OF ASIA PACIFIC ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 99
TABLE 74 LATAM ENDOMETRIOSIS MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 101
TABLE 75 LATAM ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 102
TABLE 76 LATAM ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 102
TABLE 77 LATAM ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 102
TABLE 78 BRAZIL ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 103
TABLE 79 BRAZIL ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 103
TABLE 80 BRAZIL ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 103
TABLE 81 MEXICO ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 104
TABLE 82 MEXICO ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 104
TABLE 83 MEXICO ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 105
TABLE 84 ARGENTINA ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 105
TABLE 85 ARGENTINA ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 105
TABLE 86 ARGENTINA ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 106
TABLE 87 REST OF LATIN AMERICA ENDOMETRIOSIS MARKET, BY TREATMENT, 2019-2035 (USD MILLION) 106
TABLE 88 REST OF LATIN AMERICA ENDOMETRIOSIS MARKET, BY MEDICATION, 2019-2035 (USD MILLION) 106
TABLE 89 REST OF LATIN AMERICA ENDOMETRIOSIS MARKET, BY END USE, 2019-2035 (USD MILLION) 107
TABLE 90 MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY COUNTRY, 2019-2035 (USD MILLION) 108
TABLE 91 MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 108
TABLE 92 MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 109
TABLE 93 MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 109
TABLE 94 GCC COUNTRIES ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 109
TABLE 95 GCC COUNTRIES ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 110
TABLE 96 GCC COUNTRIES ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 110
TABLE 97 SOUTH AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 111
TABLE 98 SOUTH AFRICA ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 111
TABLE 99 SOUTH AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 111
TABLE 100 REST OF MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2035 (USD MILLION) 112
TABLE 101 REST OF MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, FOR MEDICATION, 2019-2035 (USD MILLION) 112
TABLE 102 REST OF MIDDLE EAST AND AFRICA ENDOMETRIOSIS TREATMENT MARKET, BY END USE, 2019-2035 (USD MILLION) 113
TABLE 103 PRODUCT APPROVAL 118
TABLE 104 PFIZER INC.: PRODUCTS OFFERED 121
TABLE 105 PFIZER INC.: KEY DEVELOPMENTS 121
TABLE 106 MEDTRONIC: SERVICES OFFERED 125
TABLE 110 ABBVIE, INC.: PRODUCTS OFFERED 137
TABLE 111 BAYER AG: PRODUCT OFFERED 143
TABLE 112 SANOFI.: PRODUCTS OFFERED 148
TABLE 113 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED 152
TABLE 114 SUN PHARMACEUTICAL INDUSTRIES LTD. : PRODUCT OFFERED 156